Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D002066:Busulfan / Q000627:therapeutic use; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008558:Melphalan / Q000008:administration & dosage; D011034:Podophyllotoxin / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use